Ipamorelin

Research Overview

Ipamorelin was first characterized in research published in Endocrinology and the European Journal of Endocrinology in the late 1990s. It distinguished itself from earlier GH secretagogues like GHRP-6 and GHRP-2 through its selective GH-releasing activity. Studies in animal models demonstrated that Ipamorelin produced dose-dependent GH release without the concurrent elevation of cortisol and prolactin observed with less selective compounds. This selectivity has made it a preferred tool for GH research where minimizing hormonal confounders is important. Research has also examined its synergistic effects when combined with GHRH analogs like CJC-1295, as the two compounds act through complementary receptor pathways — GHRH receptor and GHS receptor, respectively.

Key Research Findings

• 1

  Demonstrated selective GH release without significant cortisol or prolactin elevation in animal models (Raun et al., 1998)

• 2

  Acts as a ghrelin receptor (GHS-R1a) agonist with high selectivity in binding assays

• 3

  Showed synergistic GH-releasing effects when combined with CJC-1295 in pharmacological studies

• 4

  Maintained efficacy across repeated administrations without significant tachyphylaxis in animal models

• 5

  Produced dose-dependent, pulsatile GH release patterns in pharmacokinetic studies

• 6

  Considered the most selective GHRP-class peptide studied to date in preclinical literature

Where to Buy Ipamorelin

Our top-ranked vendors for sourcing research-grade Ipamorelin. All vendors below publish third-party COAs and have been independently evaluated.

Related Peptides